生物
微生物群
抗生素
免疫学
微生物学
肠道微生物群
粪便细菌疗法
肠道微生物群
生物信息学
艰难梭菌
作者
Jotham Suez,Niv Zmora,Gili Zilberman-Schapira,Uria Mor,Mally Dori-Bachash,Stavros Bashiardes,Maya Zur,Dana Regev-Lehavi,Rotem Ben-Zeev Brik,Sara Federici,Max Horn,Yotam Cohen,Andreas E. Moor,David Zeevi,Tal Korem,Eran Kotler,Alon Harmelin,Shalev Itzkovitz,Nitsan Maharshak,Oren Shibolet
出处
期刊:Cell
[Elsevier]
日期:2018-09-01
卷期号:174 (6): 1406-1423.e16
被引量:1069
标识
DOI:10.1016/j.cell.2018.08.047
摘要
Summary
Probiotics are widely prescribed for prevention of antibiotics-associated dysbiosis and related adverse effects. However, probiotic impact on post-antibiotic reconstitution of the gut mucosal host-microbiome niche remains elusive. We invasively examined the effects of multi-strain probiotics or autologous fecal microbiome transplantation (aFMT) on post-antibiotic reconstitution of the murine and human mucosal microbiome niche. Contrary to homeostasis, antibiotic perturbation enhanced probiotics colonization in the human mucosa but only mildly improved colonization in mice. Compared to spontaneous post-antibiotic recovery, probiotics induced a markedly delayed and persistently incomplete indigenous stool/mucosal microbiome reconstitution and host transcriptome recovery toward homeostatic configuration, while aFMT induced a rapid and near-complete recovery within days of administration. In vitro, Lactobacillus-secreted soluble factors contributed to probiotics-induced microbiome inhibition. Collectively, potential post-antibiotic probiotic benefits may be offset by a compromised gut mucosal recovery, highlighting a need of developing aFMT or personalized probiotic approaches achieving mucosal protection without compromising microbiome recolonization in the antibiotics-perturbed host.
科研通智能强力驱动
Strongly Powered by AbleSci AI